Korean Medicine (KM)-Application Center, Korea Institute of Oriental Medicine (KIOM), 70, Cheomdan-ro, Dong-gu, Daegu 41062, Republic of Korea.
Helixmith, 21, Magokjungang 8-ro 7-gil, Gangseo-gu, Seoul 07794, Republic of Korea.
Int J Mol Sci. 2022 Nov 29;23(23):14964. doi: 10.3390/ijms232314964.
We determined the effects of two extracts from Thumb. leaves (hot water extract KIOM-2015EW and 25% ethanol extract KIOM-2015EE) in a benzalkonium chloride (BAC)-induced dry eye mouse model. Dry eye was induced by 0.2% BAC for 2 weeks, followed by treatment three times (eye drop) or once (oral administration) daily with KIOM-2015E for 2 weeks. Treatment with both KIOM-2015EE and KIOM-2015EW resulted in a marked increase in tear volume production for the 4 days of treatment. The Lissamine Green staining score, TUNEL-positive cells, and inflammatory index were significantly decreased after 2 weeks. Topical KIOM-2015EE administration exhibited a greater improvement in decreasing the ocular surface staining scores, inflammation, dead cells, and increasing tear production in a dose-dependent manner compared with the other groups. Furthermore, KIOM-2015E significantly reduced the phosphorylation of NF-κB, which was activated in the BAC-treated cornea. Topical administration was much more effective than oral administration for KIOM-2015E and KIOM-2015EE was more effective than KIOM-2015EW. Application of KIOM-2015E resulted in clinical improvement, inhibited the inflammatory response, and alleviated signs of dry eye. These results indicate that KIOM-2015E has potential as a therapeutic agent for the clinical treatment of dry eye.
我们研究了两种来自拇指叶的提取物(热水提取物 KIOM-2015EW 和 25%乙醇提取物 KIOM-2015EE)在苯扎氯铵(BAC)诱导的干眼症小鼠模型中的作用。干眼症通过 0.2% BAC 诱导 2 周,然后用 KIOM-2015E 治疗 2 周,每天 3 次(滴眼)或 1 次(口服)。KIOM-2015EE 和 KIOM-2015EW 治疗均导致治疗 4 天的泪液体积产生明显增加。Lissamine Green 染色评分、TUNEL 阳性细胞和炎症指数在 2 周后显著降低。与其他组相比,局部 KIOM-2015EE 给药在减少眼部表面染色评分、炎症、死细胞和增加泪液产生方面表现出更大的改善,呈剂量依赖性。此外,KIOM-2015E 显著降低了 BAC 处理角膜中激活的 NF-κB 的磷酸化。与口服给药相比,局部给药对 KIOM-2015E 和 KIOM-2015EE 的效果更好,而 KIOM-2015EE 比 KIOM-2015EW 更有效。KIOM-2015E 的应用导致临床改善,抑制了炎症反应,并缓解了干眼症的症状。这些结果表明,KIOM-2015E 有潜力作为干眼症临床治疗的治疗剂。